RethinkPeptides
ArticlesTopicsResearch

Amylin Analogs

3 articles in this topic.

Complete Guides

Amylin AnalogsGuide

Pramlintide: Why This Diabetes Drug Failed

Pramlintide (Symlin) is the only FDA-approved amylin analog for diabetes. It works, but dosing complexity and GLP-1 drug competition killed adoption.

18 min read|Mar 20, 2026

All Articles

Amylin Analogs

Amylin + GLP-1 Combinations for Obesity

CagriSema combines cagrilintide (amylin) and semaglutide (GLP-1) for 20.4% weight loss in phase 3 trials. The science behind dual-hormone obesity treatment.

15 min read|Mar 26, 2026
Amylin Analogs

Cagrilintide: Amylin Reimagined for GLP-1

Cagrilintide is a long-acting amylin analog that achieved 20.4% weight loss combined with semaglutide in the REDEFINE 1 Phase 3 trial of 3,417 adults.

13 min read|Mar 21, 2026

RethinkPeptides

Evidence-based peptide education. No hype, no sales. Just science.

Navigate

All ArticlesTopicsResearch DatabaseEvidence MethodologyDownload DataSearch

About

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of Use

Disclaimer

Content on RethinkPeptides is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. Peptides discussed here may not be approved for human use in your jurisdiction.

© 2026 RethinkPeptides. All rights reserved.